Pharmaceutical

What’s next for AAV gene therapies in 2024?

Upcoming regulatory events for pipeline AAV gene therapies, with a focus on neuromuscular and blood disorders, are setting high expectations for the space in 2024.

Mar 11, 2024 - 00:00
What’s next for AAV gene therapies in 2024?
Upcoming regulatory events for pipeline AAV gene therapies, with a focus on neuromuscular and blood disorders, are setting high expectations for the space in 2024.
Read the original article

Tags:

Previous Article

Opinion: STAT readers on new CDC Covid guidelines, weight loss drugs and mental ...

Next Article

Have metalenses expanded their reach into the ultraviolet region?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Debt ceiling deal could mean cancer, disease research cuts, advocates warn

STAT+: Debt ceiling deal could mean cancer, disease res...

Jun 2, 2023

Pfizer’s multiple myeloma treatment secures conditional approval in EU

Pfizer’s multiple myeloma treatment secures conditional...

Dec 8, 2023

Syndax agrees funding with Royalty Pharma for Niktimvo US sales

Syndax agrees funding with Royalty Pharma for Niktimvo ...

Nov 5, 2024